R01 HL087188/HL/NHLBI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2007	1
2008	3
2009	2
2010	3
2012	2
2013	2
2014	1
2015	2
2016	1
2024	0

1

The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.

Mian YA, Zeleznik-Le NJ. Mian YA, et al. Leuk Res. 2016 Jul;46:51-60. doi: 10.1016/j.leukres.2016.04.006. Epub 2016 Apr 16. Leuk Res. 2016. PMID: 27123834 Free PMC article.

2

FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.

You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G, Nand S, Breuer EK, Kuo PC, Breslin P, Kini AR, Nishimura MI, Zeleznik-Le NJ, Zhang J. You D, et al. Cell Rep. 2015 Mar 31;10(12):2055-68. doi: 10.1016/j.celrep.2015.02.056. Epub 2015 Mar 19. Cell Rep. 2015. PMID: 25801032 Free PMC article.

3

WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.

Brockway S, Zeleznik-Le NJ. Brockway S, et al. Cancer Genet. 2015 May;208(5):279-87. doi: 10.1016/j.cancergen.2015.01.001. Epub 2015 Jan 20. Cancer Genet. 2015. PMID: 25732734 Free PMC article.

4

Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Velu CS, et al. J Clin Invest. 2014 Jan;124(1):222-36. doi: 10.1172/JCI66005. Epub 2013 Dec 16. J Clin Invest. 2014. PMID: 24334453 Free PMC article.

5

Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.

Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, Bushweller JH, Zeleznik-Le NJ. Risner LE, et al. J Biol Chem. 2013 Oct 11;288(41):29901-10. doi: 10.1074/jbc.M113.474858. Epub 2013 Aug 29. J Biol Chem. 2013. PMID: 23990460 Free PMC article.

6

Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML.

Lokken AA, Zeleznik-Le NJ. Lokken AA, et al. Cancer Cell. 2012 Apr 17;21(4):451-3. doi: 10.1016/j.ccr.2012.03.027. Cancer Cell. 2012. PMID: 22516254 Free PMC article.

7

miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J. Li Z, et al. Nat Commun. 2012 Feb 21;3:688. doi: 10.1038/ncomms1681. Nat Commun. 2012. PMID: 22353710 Free PMC article.

8

Glycogen synthase kinase-3 and leukemia: restoring the balance.

Birch NW, Zeleznik-Le NJ. Birch NW, et al. Cancer Cell. 2010 Jun 15;17(6):529-31. doi: 10.1016/j.ccr.2010.05.017. Cancer Cell. 2010. PMID: 20541696 Free PMC article.

9

MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets.

Mian YA, Zeleznik-Le NJ. Mian YA, et al. Curr Drug Targets. 2010 Jul;11(7):801-11. doi: 10.2174/138945010791320872. Curr Drug Targets. 2010. PMID: 20370647 Free PMC article. Review.

10

Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, Bushweller JH. Cierpicki T, et al. Nat Struct Mol Biol. 2010 Jan;17(1):62-8. doi: 10.1038/nsmb.1714. Epub 2009 Dec 13. Nat Struct Mol Biol. 2010. PMID: 20010842 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year